退伍军人健康管理局中接种疫苗后仍发生重型COVID-19的血液系统肿瘤成人患者
这项病例对照研究纳入退伍军人健康管理局全国6122例接种疫苗后感染SARS-CoV-2的血液系统肿瘤患者,其中1301例(21.3%)为重型COVID-19。多因素logistic回归显示,年龄每增加1岁(aOR 1.05;95%CI 1.04-1.06)、使用抗肿瘤或免疫抑制药物(如联合糖皮质激素:aOR 2.32;95%CI 1.93-2.80)、每增加一种合并症(aOR 1.35;95%CI 1.29-1.43)与重型风险升高相关;加强针与风险降低相关(aOR 0.73;95%CI 0.62-0.86)。2022年3月口服抗病毒药广泛使用后,538例感染者中20例(3.7%)进展为重型。提示血液系统肿瘤患者接种疫苗后至2022年中重型风险仍高,尤其需要治疗者。
要点
- 6122例接种疫苗后感染SARS-CoV-2的血液系统肿瘤患者中,1301例(21.3%)发生重型COVID-19。
- 年龄每增加1岁与重型风险升高相关(aOR 1.05;95%CI 1.04-1.06)。
- 使用抗肿瘤或免疫抑制药物(如联合糖皮质激素)与重型风险升高相关(aOR 2.32;95%CI 1.93-2.80)。
- 每增加一种合并症与重型风险升高相关(aOR 1.35;95%CI 1.29-1.43);加强针与风险降低相关(aOR 0.73;95%CI 0.62-0.86)。
- 2022年3月口服抗病毒药广泛使用后,538例感染者中20例(3.7%)进展为重型。
适用人群与场景
- 退伍军人健康管理局全国范围内有血液系统恶性肿瘤诊断编码、有记录接种疫苗后发生SARS-CoV-2感染且可评估疾病严重程度的患者。
- 数据收集时间2020年1月1日至2023年4月5日,感染数据收集时间2021年1月1日至2022年9月30日。
- 病例为重型COVID-19患者,对照为非重型SARS-CoV-2感染者。
诊断标准与关键阈值
- 重型COVID-19定义:28天内死亡、机械通气、或因低氧血症证据或使用补充氧气而住院并使用地塞米松。
研究设计与关键结果
- 病例对照研究,纳入6122例患者(5844例[95.5%]男性,平均[SD]年龄70.89[11.57]岁),其中1301例(21.3%)为重型COVID-19。
- 年龄每增加1岁与重型风险升高相关(aOR 1.05;95%CI 1.04-1.06)。
- 使用抗肿瘤或免疫抑制药物(如联合糖皮质激素)与重型风险升高相关(aOR 2.32;95%CI 1.93-2.80)。
- 每增加一种合并症与重型风险升高相关(aOR 1.35;95%CI 1.29-1.43);合并症包括阿尔茨海默病或痴呆、慢性肾脏病、慢性阻塞性肺疾病、糖尿病、心力衰竭和外周血管疾病。
- 加强针接种与重型风险降低相关(aOR 0.73;95%CI 0.62-0.86)。
- 2022年3月口服抗病毒药广泛使用后,538例SARS-CoV-2感染患者中20例(3.7%)进展为重型COVID-19。
证据类型、等级与局限
- 研究类型:病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于接种疫苗后感染SARS-CoV-2的血液系统肿瘤患者,尤其高龄、正在接受抗肿瘤或免疫抑制药物(如联合糖皮质激素)治疗或合并症较多者,仍应警惕重型COVID-19风险。
- 加强针接种与重型风险降低相关(aOR 0.73;95%CI 0.62-0.86)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: With SARS-CoV-2 transforming into an endemic disease and with antiviral treatments available, it is important to establish which patients remain at risk of severe COVID-19 despite vaccination.
OBJECTIVE: To quantify the associations of clinical and demographic variables with odds of severe COVID-19 among patients with hematologic cancers.
DESIGN, SETTING, AND PARTICIPANTS: This case-control study included all patients with hematologic malignant neoplasms in the national Veterans Health Administration (VHA) who had documented SARS-CoV-2 infection after vaccination. Groups of patients with severe (cases) vs nonsevere (controls) COVID-19 were compared. Data were collected between January 1, 2020, and April 5, 2023, with data on infection collected between January 1, 2021, and September 30, 2022. All patients with diagnostic codes for hematologic malignant neoplasms who had documented vaccination followed by documented SARS-CoV-2 infection and for whom disease severity could be assessed were included. Data were analyzed from July 28 to December 30, 2023.
EXPOSURES: Clinical (comorbidities, predominant viral variant, treatment for malignant neoplasm, booster vaccination, and antiviral treatment) and demographic (age and sex) variables shown in prior studies to be associated with higher or lower rates of severe COVID-19. Comorbidities included Alzheimer disease or dementia, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, heart failure, and peripheral vascular disease.
MAIN OUTCOME AND MEASURES: The main outcome was severe COVID-19 compared with nonsevere SARS-CoV-2 infection. Severe COVID-19 was defined as death within 28 days, mechanical ventilation, or hospitalization with use of dexamethasone or evidence of hypoxemia or use of supplemental oxygen. Multivariable logistic regression was used to estimate the associations of demographic and clinical variables with the odds of severe COVID-19, expressed as adjusted odds ratios (aORs) with 95% CIs.
RESULTS: Among 6122 patients (5844 [95.5%] male, mean [SD] age, 70.89 [11.57] years), 1301 (21.3%) had severe COVID-19. Age (aOR per 1-year increase, 1.05; 95% CI, 1.04-1.06), treatment with antineoplastic or immune-suppressive drugs (eg, in combination with glucocorticoids: aOR, 2.32; 95% CI, 1.93-2.80), and comorbidities (aOR per comorbidity, 1.35; 95% CI, 1.29-1.43) were associated with higher odds of severe disease, whereas booster vaccination was associated with lower odds (aOR, 0.73; 95% CI, 0.62-0.86). After oral antiviral drugs became widely used in March 2022, 20 of 538 patients (3.7%) with SARS-CoV-2 infection during this period had progression to severe COVID-19.
CONCLUSIONS AND RELEVANCE: In this case-control study of patients with hematologic cancers, odds of severe COVID-19 remained high through mid-2022 despite vaccination, especially in patients requiring treatment.
参考来源
- Anand ST, Vo AD, La J, et al. Severe COVID-19 in Vaccinated Adults With Hematologic Cancers in the Veterans Health Administration. JAMA Netw Open. 2024. PMID: 38393725. doi:10.1001/jamanetworkopen.2024.0288
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。